WASHINGTON, Oct. 29 (Xinhua) -- American biotechnology company Moderna said on Thursday it is preparing for the launch of its COVID-19 vaccine candidate globally.

"We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," said Moderna CEO Stephane Bancel in a statement.

In addition to the Phase 3 study of the COVID-19 vaccine mRNA-1273, which is fully enrolled, Moderna now has four programs in Phase 2 studies, according to Bancel.

"Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273," he said.

On Oct. 22, the Phase 3 study of mRNA-1273 completed enrollment of 30,000 participants with approximately 37 percent of participants from diverse communities.

The Phase 1 interim analysis of the vaccine, published in The New England Journal of Medicine on July 14, showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2.